29Jul
29Jul
Siamab Therapeutics Announces Publication in PLOS ONE of Positive Data from Preclinical Studies of its ST1 Antibody Therapeutic in Development for Ovarian Cancer
Siamab Therapeutics, Inc., a biopharmaceutical company developing novel glycan-targeted cancer therapeutics, today announced the publication of positive preclinical data for its ST1 antibody drug conjugate (ADC) in multiple models of ovarian cancer. Siamab’s lead ST1 program targets Sialyl-Tn (STn), a tumor-associated carbohydrate antigen (TACA), which is expressed on ovarian and other solid tumors and is associated with metastatic disease, poor prognosis, chemo-resistance, and reduced overall survival. Read more >>
27Jul
High-tech brace allows Mechanicsburg teen use left arm again
Dees is the first adolescent worldwide to use the MyoPro 2 — a powered arm brace designed to restore movement to paralyzed or weakened arms — out of trials, according to Jonathan Naft, vice president of Myomo, a medical robotics company based in Cambridge, Massachusetts, that takes it names from “my own motion.” Read more >>
27Jul
Fireside Chat with Mic Williams (Founder of Boston Harbor Angels)
Mic (Michael) Williams has been an investor for over 35 years. Whereas his primary investments and have been in commercial real estate; his previous private investments have included manufacturing, mining, movies, lumber products, ships and a television enterprise. He founded Boston Harbor Angels eleven years ago and has invested in 25+ deals. He has had several very successful exits with Smart Cells (Merck $500MM and Carbonite-IPO, Corbus Pharmaceuticals Holdings Inc.CRBP NASD,) There are more than several auspicious horses still in his...
26Jul
Corbus Pharmaceuticals to Commence Phase 3 Study of Lenabasum for the Treatment of Rare Autoimmune Disease Dermatomyositis
Corbus Pharmaceuticals Holdings, Inc., a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that the Company will proceed with a Phase 3 trial evaluating the efficacy and safety of lenabasum for the treatment of dermatomyositis (“DM”). Dermatomyositis is a rare and serious multisystem inflammatory autoimmune disease affecting muscle and skin. The U.S. Food and Drug Administration (“FDA”) provided guidance on the overall study design of this trial at a recent end-of-Phase 2 meeting....
24Jul
With New Branding and Strategy, Premama Targets Millennial Moms
Consumers are looking to niche, distinctly branded wellness products for everything from their heart and gut health, to their skin and hair care. With a new look, reformulated products and new offerings, female-focused nutrition company Premama is hoping women shoppers will consider how their diets can impact the many stages of motherhood, too. Read more >>
24Jul
Guide: 12 Boston Startups That Tackle the $1.3 Trillion Student Debt Problem
MIT grad Laurel Taylor created FutureFuel in Boston to tackle two problems: the need for students to pay off debt and the need for employers to hire qualified STEM talent (which currently has a huge shortage). Read more >>
21Jul
Johns Hopkins spinout Neuraly launches with $36M funding round
The Maryland biotech startup is developing new treatments for Parkinson's disease and Alzheimer’s disease. Read more >>
21Jul
Corbus Pharmaceuticals Receives FDA Orphan Drug Designation for Lenabasum for the Treatment of Dermatomyositis
Corbus Pharmaceuticals Holdings, Inc., a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases, announced today that the U.S. Food and Drug Administration has granted Orphan Drug Designation to lenabasum, its novel, synthetic oral endocannabinoid-mimetic drug, for the treatment of dermatomyositis. Read more >>
19Jul